Therapeutic advances in idiopathic pulmonary fibrosis
Emily Fraser and Rachel K Hoyles
DOI: https://doi.org/10.7861/clinmedicine.16-1-42
Clin Med February 2016 Emily Fraser
AOxford Interstitial Lung Disease Service, Churchill Hospital, Oxford, UK
Roles: research fellow
Rachel K Hoyles
BOxford Interstitial Lung Disease Service, Churchill Hospital, Oxford, UK
Roles: consultant respiratory physician
Article Information
vol. 16 no. 1 42-51
PubMed:
Published By:
Print ISSN:
Online ISSN:
History:
- Published online February 1, 2016.
Copyright & Usage:
© Royal College of Physicians 2016. All rights reserved.
Author Information
- AOxford Interstitial Lung Disease Service, Churchill Hospital, Oxford, UK
- BOxford Interstitial Lung Disease Service, Churchill Hospital, Oxford, UK
- Address for correspondence: Dr RK Hoyles, Oxford Interstitial Lung Disease Service, Churchill Hospital, Oxford OX3 7LE, UK. Email: rachel.hoyles{at}ouh.nhs.uk
Article usage
Article Tools
Therapeutic advances in idiopathic pulmonary fibrosis
Emily Fraser, Rachel K Hoyles
Clinical Medicine Feb 2016, 16 (1) 42-51; DOI: 10.7861/clinmedicine.16-1-42
Citation Manager Formats
Jump to section
- Article
- ABSTRACT
- Background
- Defining the diagnosis of IPF
- Overall management principles
- Approaches to management
- Pharmacological treatment options
- Pirfenidone
- Nintedanib
- Managing side effects of pirfenidone and nintedanib
- Other considerations
- Pulmonary rehabilitation
- Anti-acid therapy
- Current and future trials
- Summary
- References
- Figures & Data
- Info & Metrics
Related Articles
- No related articles found.
Cited By...
- No citing articles found.